



DEPARTMENT OF HEALTH & HUMAN SERVICES

NDA 20-444/S-003

Food and Drug Administration  
Rockville MD 20857

Glaxo Wellcome, Inc.  
Attention: Roger Gaby  
Project Director, Regulatory Affairs  
Five Moore Drive  
Research Triangle, NC 27709

APR 14 2000

Dear Mr. Gaby:

Please refer to your supplemental new drug application dated December 11, 1998, received December 14, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Flolan (epoprostenol sodium) for Injection.

We acknowledge receipt of your submission dated December 22, 1999. Your submission of October 13, 1999 constituted a complete response to our May 26, 1999 action letter.

This supplemental new drug application provides for the use of Flolan (epoprostenol sodium) for Injection for the long-term intravenous treatment of pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-444/S-003." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

NDA 20-444/S-003

Page 2

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Brian Strongin, Project Manager, at (301) 827-7310.

Sincerely,



Lilia Talarico, M.D.  
Director  
Division of Gastrointestinal and Coagulation Drug  
Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

Enclosure